1. Signaling Pathways
  2. Cytoskeleton
  3. Myosin

Myosin

Myosins are mechanoenzymes that interact with actin filaments and hydrolyse ATP to generate movement and force. This enables myosins to propel the sliding of actin filaments, to produce tension on actin filaments and to walk along these filaments. As a result, myosins can regulate the structure and dynamics of the actin cytoskeleton and affect the localization and transport of cellular components. The different myosins are grouped into classes on the basis of their motor domains. There are 35 known classes of myosin, and humans have 40 myosin genes that fall into 13 classes (I, II, III, V, VI, VII, IX, X, XV, XVI, XVIII, XIX and XXXV).

Myosins are actin-dependent motors that participate in a diverse range of crucial activities, including muscle contraction, intracellular trafficking, cell division, motility, actin cytoskeletal organisation and cell signaling. Myosin malfunction has been implicated in a variety of disorders including deafness, hypertrophic cardiomyopathy, Usher syndrome, Griscelli syndrome and cancer.

Myosin light chain kinase (MLCK) is an enzyme that activates the myosin light chain to exert its function related to cytoskeleton contraction and tight junction regulation. In most cells, MLCK is a transducer for signalling MLC phosphorylation in response to Ca2+ binding to MLCK-associated calmodulin. MLCK-mediated MLC phosphorylation and actomyosin contractility is important in muscle contraction, cell migration, and endo/exocytic processes, and is recognized for its central role in signalling endothelial cell-cell adhesion and barrier function.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-143657
    Myoferlin inhibitor 1
    99.88%
    Myoferlin inhibitor 1 is a novel agent against pancreatic cancer metastasis through targeting myoferlin.
    Myoferlin inhibitor 1
  • HY-152190
    JB002
    Inhibitor 99.32%
    JB002 is a myosin II inhibitor, with an IC50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.
    JB002
  • HY-141810
    MT-134
    Inhibitor
    MT-134 is a SkMII-specific inhibitor and has excellent exposure in muscles.
    MT-134
  • HY-100984A
    HA-100 hydrochloride
    Inhibitor
    HA-100 hydrochloride is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCK inhibitor.
    HA-100 hydrochloride
  • HY-13441G
    (-)-Blebbistatin (GMP)
    Inhibitor
    (-)-Blebbistatin (GMP) is (-)-Blebbistatin (HY-13441) produced by using GMP guidelines. (-)-Blebbistatin (GMP) is a selective inhibitor of the ATPase activity of non-muscle myosin II.
    (-)-Blebbistatin (GMP)
  • HY-128482
    Diazobenzenesulfonic acid
    Inhibitor
    Diazobenzenesulfonic acid (4-Sulfobenzenediazonium) is an inhibitor of aliostericeffect for myosin ATPase 13.
    Diazobenzenesulfonic acid
  • HY-12880
    HA-100 dihydrochloride
    Inhibitor
    HA-100 dihydrochloride is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 dihydrochloride also used as a ROCK inhibitor.
    HA-100 dihydrochloride
  • HY-139622
    DN-F01
    Inhibitor
    DN-F01 has a strong inhibitory calcium-dependent effect on cardiac myofibrillar ATPase activity with an IC50 value of 11 ± 4 nmol/L.
    DN-F01
  • HY-161608
    Myosin modulator 1
    Modulator
    Myosin modulator 1 (Compound B141) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 0.42, 0.13 and 3.09 μM, respectively. Myosin modulator 1 regulates systolic cardiac performance in Sprague Dawley rats.
    Myosin modulator 1
  • HY-122200R
    Phenamacril (Standard)
    Inhibitor
    Phenamacril (Standard) is the analytical standard of Phenamacril. This product is intended for research and analytical applications. Phenamacril (JS399-19) inhibits activity of myosin I non-competitively with an IC50 of 360 nM through suppression of the ATPase activity, exhibits therefore an antifungal efficacy towards Fusarium species.
    Phenamacril (Standard)
  • HY-169183
    Myokinasib-II
    Inhibitor
    Myokinasib-II is a myosin light chain kinase (MLCK) inhibitor, which is a potential target for inflammatory diseases, cancer and other diseases..
    Myokinasib-II
  • HY-161609
    Myosin modulator 2
    Modulator
    Myosin modulator 2 (Compound B172) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 2.013, 2.94 and 20.93 μM, respectively. Myosin modulator 2 regulates systolic cardiac performance in Sprague Dawley rats.
    Myosin modulator 2
  • HY-170318
    Adhibin
    Inhibitor
    Adhibin is an allosteric inhibitor for RhoGAP class IX myosin, that inhibits Myo9 ATPase in mammalian and invertebrate with IC50 of 2.5 µM and 2.6 µM. Adhibin binds to the ATPase of myosin, interfers with its motor function, blocks the RhoGTPase related signaling pathway, and affects the cell migration, adhesion and cell division. Adhibin can be used in research about cancer metastasis.
    Adhibin
  • HY-14233S
    Omecamtiv mecarbil-d8
    Activator
    Omecamtiv mecarbil-d8 is the deuterium labeled Omecamtiv mecarbil. Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
    Omecamtiv mecarbil-d<sub>8</sub>
  • HY-N15301
    Nocarnickelamide B
    Inhibitor
    Nocarnickelamide B (Compound 2) is a linear peptide and ROCK1/2 inhibitor. Nocarnickelamide B exhibits dual inhibitory activity against ROCK1 and ROCK2 with IC50s of 14.9 μM and 21.9 μM, respectively. Nocarnickelamide B binds to the ATP-binding site. Nocarnickelamide B inhibits the activation of ROCK-regulated cytoskeletal contraction markers such as the myosin light chain. Nocarnickelamide B is potential for glaucoma reasearch.
    Nocarnickelamide B
  • HY-P5998
    Myosin Light Chain Kinase Substrate (smooth muscle)
    Myosin Light Chain Kinase Substrate (smooth muscle) is a smooth muscle myosin light chain kinase (MLCK) synthetic peptide substrate.
    Myosin Light Chain Kinase Substrate (smooth muscle)
  • HY-168529
    NU074381b
    Inhibitor
    NU074381b (compound 5b) is a potent S100A4 inhibitor. NU074381b inhibits S100A4-NMII complex formation with an IC50 value of 0.48 µM. NU074381b inhibits cell proliferation and migration.
    NU074381b
  • HY-109037S
    Mavacamten-d6
    Modulator
    Mavacamten-d6 (MYK461-d6; SAR439152-d6) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
    Mavacamten-d<sub>6</sub>
  • HY-133885A
    R-(-)-7-Desmethyl-8-nitro blebbistatin
    Control
    R-(-)-7-Desmethyl-8-nitro blebbistatin is an analog of (-)-Blebbistatin (HY-13441). (-)-Blebbistatin is a selective non-muscle myosin II inhibitor.
    R-(-)-7-Desmethyl-8-nitro blebbistatin
  • HY-109037S4
    Mavacamten-d7
    Modulator
    Mavacamten-d7 (MYK461-d7) is deuterium labeled Mavacamten. Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
    Mavacamten-d<sub>7</sub>
Cat. No. Product Name / Synonyms Application Reactivity